RepligenRGEN +9.56%83 Gross Margin % is 55.74% as of Mar. 2026, which is 1% above its 10-year median of 55.17. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Repligen ranks better than 51.55% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Repligen's Gross Profit for the
three
months ended in Mar. 2026 was $108.3 Mil. Repligen's Revenue for the
three
months ended in Mar. 2026 was $194.3 Mil. Therefore, Repligen's Gross Margin % for the quarter that ended in Mar. 2026 was 55.74%.
Warning Sign:
Repligen Corp gross margin has been in long-term decline. The average rate of decline per year is -4.5%.
The historical rank and industry rank for Repligen's Gross Margin % or its related term are showing as below:
RGEN'
s Gross Margin % Range Over the Past 10 Years
Min: 43.29 Med: 55.17 Max: 58.35
Current: 52.9
During the past 13 years, the highestGross Margin % of Repligen was 58.35%. The lowest was 43.29%. And the median was 55.17%.
RGEN's Gross Margin % is ranked better than 51.55% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs RGEN: 52.90
Repligen had a gross margin of 55.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Repligen was -4.50% per year.
Repligen (NAS:RGEN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Repligen had a gross margin of 55.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Repligen Gross Margin % Related Terms
Repligen Gross Margin % Historical Data
* Premium members only.
The historical data trend for Repligen's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Repligen's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Repligen (RGEN) has a Gross Margin % of 55.74% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Repligen and its competitors. This is near median its historical median of 55.17. Over the past decade, Repligen's Gross Margin % has ranged from 43.29 to 58.35. According to the industry distribution chart, Repligen ranks #390 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 48.4%.
Is Repligen's Gross Margin % too high?
Repligen's current Gross Margin % of 55.74% is near median its 10-year median of 55.17. Over the past 10 years, this metric has ranged from a low of 43.29 to a high of 58.35. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Repligen's value of 55.74% is 7% above this industry median. Based on the distribution chart, Repligen ranks #390 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Gross Margin % compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #390 out of 805 companies for Gross Margin %. This puts Repligen in the upper half of its industry. The industry median Gross Margin % is 52.07. Repligen's value of 55.74% is 7% above this benchmark. Historically, Repligen's own Gross Margin % has ranged from 43.29 to 58.35 over the past decade. While the company's 10-year median is 55.17 vs. the industry median of 52.07, Repligen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current Gross Margin % of 55.74% is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current Gross Margin % is 55.74%, which is near median its own 10-year median of 55.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.47 — trading 21.3% below its estimated fair value. The current Gross Margin % is 55.74%, which is near median its 10-year median of 55.17 and 7% above the Medical Devices & Instruments industry median of 52.07. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Repligen (RGEN), the current Gross Margin % is 55.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $138.47 is trading 21.3% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
Gross Margin %: 55.74% (near median its 10-year median of 55.17)
GF Value™: $175.89 vs. price of $138.47 (21.3% below fair value)
Industry Position: 7% above the Medical Devices & Instruments median (#390 of 805)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
